Allianz Asset Management
SLNO

Allianz Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Allianz Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,100
Closed -$1.07M – 2244
2024
Q1 		$1.07M Buy
+25,100
New +$1.14M ﹤0.01% 1389

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Allianz Asset Management's SLNO Position: Q2 2024 in Review

Allianz Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2024, closing a stake of 25,100 shares — an estimated $1.07M sold.

Allianz Asset Management first reported a position in SLNO in Q1 2024 and held it in 1 quarter. The position peaked at $1.07M in Q1 2024. 114 funds tracked by Wall St. Rank hold SLNO as of Q2 2024.

  • Allianz Asset Management reported no remaining Soleno Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Allianz Asset Management sold 25,100 Soleno Therapeutics shares in Q2 2024, an estimated $1.07M.
  • Allianz Asset Management first reported a position in Soleno Therapeutics in Q1 2024 and held it in 1 quarter.
  • Allianz Asset Management's Soleno Therapeutics position peaked at $1.07M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2024.

Based on Allianz Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.